

chain nodes :

12 13 14 15 16 17 18 19 20 21 22 24

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

chain bonds :

2-6 2-22 3-13 3-14 4-15 4-20 5-16 5-21 7-19 8-18 9-24 11-12 16-17

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11

exact/norm bonds :

1-2 1-5 2-3 2-6 3-4 4-5 4-15 6-7 6-11 7-8 8-9 9-10 9-24 10-11 11-12

exact bonds :

2-22 3-13 3-14 4-20 5-16 5-21 7-19 8-18 16-17

G1:O,NH

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:CLASS13:CLASS14:CLASS15:CLASS16:CLASS17:CLASS18:CLASS19:CLASS20:CLASS21:CLASS22:CLASS24:CLASS

10/828,753

FILE 'REGISTRY' ENTERED AT 15:01:44 ON 27 DEC 2007  
L1 STRUCTURE DOWNLOADED  
L2 8 B L1 SIDE SAM  
L3 19 B L1 FULL

FILE 'CAPLOS' ENTERED AT 15:02:41 ON 27 DEC 2007  
L4 10 B L3

10/828,753

Connecting via Winsock to STN

Welcome to STN International! Enter xix

LOGTNID:iscripts16001xx

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR 7):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 AUG 06 CAS REGISTRY enhanced with new experimental property tags  
NEWS 3 AUG 06 EFTS enhanced with new thesaurus edition  
NEWS 4 AUG 13 CA/CAPLUS enhanced with additional kind codes for granted patents  
NEWS 5 AUG 20 CA/CAPLUS enhanced with CAS indexing in pre-1907 records  
NEWS 6 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB  
NEWS 7 AUG 27 HSPATGLO now available on STN  
NEWS 8 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data  
NEWS 9 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index  
NEWS 10 SEP 13 FORIS renamed to SOPIS  
NEWS 11 SEP 13 INFOCDB enhanced with monthly SDF frequency  
NEWS 12 SEP 17 CA/CAPLUS enhanced with printed CA page images from 1967-1998  
NEWS 13 SEP 17 CAPLUS coverage extended to include traditional medicine patents  
NEWS 14 SEP 24 EMBASE, EMBASEL, and EMBASEL enhanced with enhancements  
NEWS 15 OCT 02 CA/CAPLUS enhanced with pre-1907 records from Chemisches Zentralblatt  
NEWS 16 OCT 19 BELLSTEIN updated with new compounds  
NEWS 17 NOV 15 Derwent Indian patent publication number format enhanced  
NEWS 18 NOV 19 WPIX enhanced with XML display format  
NEWS 19 NOV 30 ICSD released with enhancements  
NEWS 20 DEC 04 LINDA/CDB now available on STN  
NEWS 21 DEC 14 BELLSTEIN pricing structure to change  
NEWS 22 DEC 17 UNPATGLO added to additional database clusters  
NEWS 23 DEC 17 IMBORGSCDB removed from database clusters and STN  
NEWS 24 DEC 17 EGENE now includes more than 10 million sequences  
NEWS 25 DEC 17 TOXICSTER enhanced with 2008 MeSH vocabulary in MEDLINE segment  
NEWS 26 DEC 17 MEDLINE and LMEELINE updated with 2008 MeSH vocabulary  
NEWS 27 DEC 17 CA/CAPLUS enhanced with new custom IPC display formats  
NEWS 28 DEC 17 STN Viewer enhanced with full-text patent content from HSPATGLO  
  
NEWS EXPRES 14 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V6.2, CURRENT MACINTOSH VERSION IS V6.0c(RGS) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.  
  
NEWS BOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPCS For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED BY 15:01:05 ON 27 DEC 2007

ENDSCREEN

10/828,753

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

BATCH

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:01:44 ON 27 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP DESCRIBTERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the SIC/VIGINTI data file provided by infoChem.

STRUCTURE FILE DATES: 26 DEC 2007 HIGHEST RN 959588-76-2

DICTIONARY FILE DATES: 26 DEC 2007 HIGHEST RN 959588-76-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TECA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10628753-122767.etr

LI STRUCTURE UPLOADED

=> d li

LI HAS NO ANSWERS

LI STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s li sea sam

SAMPLE SEARCH INITIATED 15:02:11 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED

0 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 0 TO 0

PROJECTED ANSWERS: 0 TO 0

LI 0 SEA 000 SAM LI

=> s li full

FULL SEARCH INITIATED 15:02:37 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 20 TO ITERATE

100.0% PROCESSED

20 ITERATIONS

10 ANSWERS

SEARCH TIME: 00.00.01

LI 10 SEA 000 FULL LI

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.55

172.76

FILE 'CAPLUS' ENTERED AT 15:02:41 ON 27 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP DESCRIBTERMS" FOR DETAILS.

@cInfolink

16/626,753

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1986), unless otherwise indicated in the original publications. The Ca Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STM. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1987 - 31 Dec 2007 VOL 147 IBS 26  
FILE LAST UPDATED: 26 Dec 2007 (20071226/EO)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/info/policy.html>

-- s 11

L4 10 L3

-- d bib abs hits 1-10 14

L4 ANSWER 1 OF 10 CAPLOS COPYRIGHT 2007 ACS on STM

AN 2007:1121735 CAPLOS

DI 147:461654

TI Characterization of the Metabolic Activation of Hepatitis C Virus Nucleoside Inhibitor  $\beta$ -D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and Identification of a Novel Active 5'-Triphosphate Species

AU Ma, Man; Jiang, Wen-Rong; Bobledo, Nicolas; Leveque, Vincent; Ali, Samir; Lara-Jaime, Teresa; Masjedizadeh, Mohammad; Smith, David S.; Cammack, Nick; Klump, Klaus; Symons, Julian

OR Roche Palo Alto LLC, Palo Alto, CA, 94304, USA

SO Journal of Biological Chemistry (2007), 282(41), 29812-29820

INDEX: JBCBIA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal

LA English

AB  $\beta$ -D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) is a potent inhibitor of hepatitis C virus (HCV) replication in the subgenomic HCV replicon system, and its corresponding 5'-triphosphate is a potent inhibitor of the HCV RNA polymerase in vitro. In this study the formation of PSI-6130-triphosphate was characterized in primary human hepatocytes. PSI-6130 and its 5'-phosphorylated derivs. were identified, and the intracellular concs. were determined. In addition, the deaminated derivative of PSI-6130,  $\beta$ -D-2'-deoxy-2'-fluoro-2'-C-methyluridine (RO2433, PSI-6026) and its corresponding phosphorylated metabolites were identified in human hepatocytes after incubation with PSI-6130. The formation of the 5'-triphosphate (TP) of PSI-6130 (PSI-6130-TP) and RO2433 (RO2433-TP) increased with time and reached steady state levels at 48 h. The formation of both PSI-6130-TP and RO2433-TP demonstrated a linear relationship with the extracellular concs. of PSI-6130 up to 100  $\mu$ M, suggesting a high capacity of human hepatocytes to generate the two triphosphates. The mean half-lives of PSI-6130-TP and RO2433-TP were 4.7 and 18 h, resp. RO2433-TP also inhibited RNA synthesis by the native HCV replicase isolated from HCV replicon cells and the recombinant HCV polymerase NS5B with potencies comparable with those of PSI-6130-TP. Incorporation of RO2433-5'-monophosphate (MP) into nascent RNA by NS5B led to chain termination similar to that of PSI-6130-MP. These results demonstrate that PSI-6130 is metabolized to two pharmacol. active species in primary human hepatocytes.

XT 817204-44-7, PSI-6130-triphosphate

PL: BSI (Biological study, unclassified); PAC (Pharmacological activity);

PXT (Pharmacokinetics); THU (Therapeutic use); BIDL (Biological study);

USES (Uses)

(characterization of metabolic activation of hepatitis C virus nucleoside inhibitor  $\beta$ -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species)


IN 817204-44-7 CAPLOS

CH cytidine 5'-(tetrahydrogen triphosphate), 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (CA INDEX NAME)

00100000

10/626,753

Absolute stereochemistry.



IT 817264-33-4, PSI-6130


RI: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOD (Biological study); UMES (Uses)

(characterization of metabolic activation of hepatitis C virus nucleoside inhibitor  $\beta$ -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species)

RM 817264-33-4 CAPLUS

CH Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on SFD

RM 2807:877688 CAPLUS

DD 147:397801

T1 Pharmacokinetics of the antiviral agent  $\beta$ -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine in rhesus monkeys

KU Asif, Ghaziz; Burwitz, Selwyn J.; Shi, Junxing; Hernandez-Santiago, Brenda I.; Schinazi, Raymond P.

CS Department of Pediatrics, Emory University, Atlanta, GA, 30322, USA

SO Antimicrobial Agents and Chemotherapy (2007), 51(8), 2877-2882

CODEN: AMACDQ; ISSN: 0950-4230

FS American Society for Microbiology

DT Journal

LA English

AB  $\beta$ -D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) is an effective inhibitor of hepatitis C virus (HCV) replication in vitro. The purpose of this study was to evaluate the single-dose pharmacokinetics of PSI-6130 in rhesus monkeys following i.v. and oral administration. Noncompartmental anal. of the serum data obtained following oral and i.v. administration was performed. Pharmacokinetic studies with rhesus monkeys indicated slow and incomplete absorption with a mean absorption time (MAT) of 4.6 h and an oral bioavailability of  $24.0\% \pm 14.3\%$  (mean  $\pm$  standard deviation), with comparable mean apparent half-lives following i.v. ( $4.58 \pm 1.98$  h) and oral ( $5.54 \pm 1.13$  h) administrations. The average percentages of the total dose recovered unchanged and in deaminated form in the urine were  $12.9\% \pm 12.4\%$  and  $18.9\% \pm 6.6\%$  (i.v.) and  $6.0\% \pm 3.9\%$  and  $3.9\% \pm 1.0\%$  (oral), resp. The total bioavailability, taking into account the parent drug and its deaminated metabolite 2'-deoxy-2'-fluoro-2'-C-methyluridine (PSI-62061), was  $44\% \pm 26\%$ . PSI-6130 was present in the cerebrospinal fluid after oral and i.v. dosing. However, no deamination of radiolabeled PSI-6130 was detected after 8 h of incubation in monkey and human whole blood. An W4-modified prodrug of PSI-6130 (PSI-6419) was orally administered to monkeys, but it failed to improve the oral bioavailability of PSI-6130. Further studies are warranted to improve the oral bioavailability and reduce the deamination of PSI-6130 in order to

Scintosh

10/828,753

explore the potential of this drug for the treatment of HIV-infected individuals.


IT 863129-66-2

RL: BSO (Biological study, unclassified); BIDL (Biological study) (PSI-6296; pharmacokinetics of antiviral deoxyfluoromethylcytidine in rhesus monkeys)

RM 863129-66-2 CAPLUS

CM Uridine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (PCI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 950923-07-62

RL: PKT (Pharmacokinetics); SEP (Synthetic preparation); THU (Therapeutic use); BIDL (Biological study); PREP (Preparation); USES (Uses) (PSI-6419; pharmacokinetics of antiviral deoxyfluoromethylcytidine in rhesus monkeys)

RM 950923-07-6 CAPLUS

CM INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




IT 817284-33-4, PSI-6130

RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIDL (Biological study); USES (Uses) (pharmacokinetics of antiviral deoxyfluoromethylcytidine in rhesus monkeys)

RM 817284-33-4 CAPLUS

CM Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LA ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACE on BTN

AN 2007:640498 CAPLUS

DE 147:53103

TI Preparation of acylated (2'R)-2'-deoxy-2'-fluoro-2'-methylcytidines as antiviral agents

IE Chen, Byoung-Eon; Clark, Jeremy; Barma, Keshab; Wang, Pilyuan

PA F. Hoffmann-La Roche A.-G., Switz.; Pharmasset Inc.

McIntosh

18/528,753

30 PCT Int. Appl. 44pp.


CODEN: F1XN02

DT Patent

LG English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007045829	A1	20070614	WO 2006-EP63060	20061129
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BP, BW, BY, BZ, CA, CH, CB, CC, CD, CE, CF, CG, CH, CI, CJ, CK, CL, CM, CN, CO, CP, CR, CS, CU, CV, CW, CX, CY, CZ, DA, DB, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DR, DS, DT, DU, DV, DW, DX, DY, DZ, EA, EB, EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL, EM, EN, EO, EP, EQ, ER, ES, ET, EU, EV, EW, EX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GF, GH, GI, GJ, GK, GL, GM, GN, GO, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MM, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NN, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RR, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TT, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ.				
US 2007197463	A1	20070823	US 2006-635899	20061208
PRAI US 2005-749318P	P	20051209		
OS CASPERACT 147:53103; MAPPER 147:53103				
GX				




AE Acylated nucleosides I (R1 = alkyl, alkoxy) and their salts, useful as antiviral agents, are prepared by acylation of I (R1 = H). Formulations containing I (R1 = 1-PrO) were given.

IT 940908-81-4P  
 RL: PAC (Pharmacological activity); RCT (Reagent); SEP (Synthetic preparation); THU (Therapeutic use); BICL (Biological study); PREP (Preparation); RACT (Reagent or reagent); USES (Uses)  
 (preparation of acylated (2'-R)-2'-deoxy-2'-fluoro-2'-methylecytidines as antiviral agents)

BN 940908-81-6 CAPLUS

CM Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-bis(propyl carbonate), (2'-R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 940908-73-1P 940908-73-2P 940908-83-5P  
 940908-87-7P  
 RL: PAC (Pharmacological activity); SEP (Synthetic preparation); THU (Therapeutic use); BICL (Biological study); PREP (Preparation); USES

McInnes

10/828,753


{Uses1

{preparation of acylated (2'R)-2'-deoxy-2'-fluoro-2'-methylcytidines as  
antiviral agents}

BN 940908-78-1 CASREG

CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dipropionate, (2'R)- (CA  
INDEX NAME)


Absolute stereochemistry.



BN 940908-78-2 CASREG

CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-bis(2-methylpropionate),  
(2'R)- (CA INDEX NAME)


Absolute stereochemistry.



BN 940908-80-5 CASREG

CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-bis(2-methylpropyl  
carbonate), (2'R)- (CA INDEX NAME)

Absolute stereochemistry.




BN 940908-82-7 CASREG

CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-bis(propyl carbonate),  
hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.

SciSearch

10/828,753



● HCl


IT 817204-33-4

KL: KCT (Reactant); PACT (Reactant or reagent)  
(preparation of acylated (2'R)-2'-deoxy-2'-fluoro-2'-methylcytidines as  
antiviral agents)

BN 817204-33-4 CAPLUS

CU Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



HE-OUT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS PEOGPG  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACE on STN

BN 2007:147983 CAPLUS

CU 144387251

T1 Mechanism of activation of  $\beta$ -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine  
and inhibition of hepatitis C virus NS5B RNA polymerase

BU Murakami, Eisuke; Bao, Haiying; Kamesh, Mangala; McBrayer, Tamara F.;  
Whitaker, Tony; Miccolinich Steuer, Holly M.; Kcinazai, Raymond P.;  
Stayer, Steven J.; Ghiknad, Aleksandr; Otto, Michael J.; Furman, Phillip  
A.

CB Pharmasset, Inc., Princeton, NJ, 08540, USA

BO Antimicrobial Agents and Chemotherapy (2007), 51(2), 503-509

CODEN: ANACCO; ISSN: 0968-4804

PN American Society for Microbiology

DT Journal

LA English


AB  $\beta$ -D-2'-Deoxy-2'-Fluoro-2'-C-methylcytidine (F31-6130) is a potent  
specific inhibitor of hepatitis C virus (HCV) RNA synthesis in Huh-7  
replicon cells. To inhibit the HCV NS5B RNA polymerase, F31-6130 must be  
phosphorylated to the 5'-triphosphate form. The phosphorylation of  
F31-6130 and inhibition of HCV NS5B were investigated. The  
phosphorylation of F31-6130 by recombinant human 2'-deoxycytidine kinase  
(dCK) and uridine-cytidine kinase 1 (UCK-1) was measured by using a  
coupled spectrophotometric reaction. F31-6130 was shown to be a substrate  
for purified dCK, with a  $K_m$  of 81  $\mu$ M and a  $k_{cat}$  of 0.007  $s^{-1}$ , but was  
not a substrate for UCK-1. F31-6130 monophosphate (F31-6130-MP) was  
efficiently phosphorylated to the diphosphate and subsequently to the  
triphosphate by recombinant human dMP-dMP Kinase and nucleoside  
diphosphate kinase, resp. The inhibition of wild-type and mutated (S282T)  
HCV NS5B RNA polymerases was studied. The steady-state inhibition constant  
( $K_i$ ) for F31-6130 triphosphate (F31-6130-TP) with the wild-type enzyme was  
4.3  $\mu$ M. Similar results were obtained with 2'-C-methyladenosine  
triphosphate ( $K_i$  = 1.5  $\mu$ M) and 2'-C-methylcytidine triphosphate ( $K_i$  =  
1.6  $\mu$ M). Consistent with the S282T mutation, which is known to confer  
resistance to 2'-C-methyladenosine, was inhibited by F31-6130-TP as  
efficiently as the wild-type. Incorporation of F31-6130-MP into RNA

McIntosh

10/828,753


catalyzed by purified NS5B RNA polymerase resulted in chain termination.  
EF 817204-44-7, PSI 6130 triphosphate 932721-63-6, PSI 6130  
monophosphate 932721-64-7, PSI 6130 diphosphate  
RL: 26U (Biological study, unclassified); BEO (Biological study;  
formation; mechanism of activation of  $\beta$ -D-2'-deoxy-2'-fluoro-2'-C-  
methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase)  
RN 817204-44-7 CASLUS  
CN Cytidine 5'-(tetrahydrogen triphosphate), 2'-deoxy-2'-fluoro-2'-methyl-,  
(2'R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 932721-63-6 CASLUS  
CN 5'-Cytidylic acid, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 932721-64-7 CASLUS  
CN Cytidine 5'-(trihydrogen diphosphate), 2'-deoxy-2'-fluoro-2'-methyl-,  
(2'R)- (CA INDEX NAME)

Absolute stereochemistry.



EF 817204-33-4, PSI 6130  
PL: BEO (biological study, unclassified); PRP (Properties); BIOG  
(Biological study)  
(mechanism of activation of  $\beta$ -D-2'-deoxy-2'-fluoro-2'-C-  
methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase)  
RN 817204-33-4 CASLUS  
CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




MolPort

18/828,753

HELCUT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 5 OF 10 CAPIUS COPYRIGHT 2007 ACS OR STM  
LN 2006:085303 CAPIUS  
DN 145:505687  
TI Synthesis of 2-deoxy-2-fluoro-2-C-methyl-β-D-ribofuranose  
AU Clark, Jeremy L.; Mason, J. Christian; Bobos, Ann J.; Hollecker, Laurent;  
Schinazi, Raymond P.  
CG Pharmasset, Inc., Tucker, GA, USA  
SO Journal of Carbohydrate Chemistry (2006), 25(6), 461-470  
CODEN: JCACDH; ISSN: 0732-8353  
PB Taylor & Francis, Inc.  
OT Journal  
LA English  
OS CASREACT 145:505687  
AB The synthesis of Me 3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-C-methyl-β-D-  
ribofuranoside and the conversion to the corresponding  
1-O-acetyl-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-C-methyl-β-D-ribofuranose and  
1,1,1-tri-O-benzoyl-2-deoxy-2-fluoro-2-C-methyl-β-D-ribofuranose is  
reported. The key synthetic step is the fluorination of the tertiary  
center of Me 3,5-di-O-benzoyl-2-C-methyl-β-D-arabinofuranoside to  
provide Me 3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-C-methyl-β-D-  
ribofuranoside.  
YP 817284-31-1P 874638-94-5P  
EL: SEP (Synthetic preparation); PREP (Preparation)  
(synthesis of 2-deoxy-2-fluoro-2-C-methyl-β-D-ribofuranose via  
fluorination of the tertiary center of Me 3,5-di-O-benzoyl-2-C-methyl-  
β-D-arabinofuranosides)  
XB 817284-32-3 CAPIUS  
CX Cytidine, 4-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoyl-,  
(2'R)- (2CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



HN 874638-94-5 CAPIUS  
CH Benzamide, 4-[1-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-methyl-α-D-  
erythro-pentofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.



HELCUT 20 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 10 CAPIUS COPYRIGHT 2007 ACS OR STM  
LN 2006:478128 CAPIUS

Maintain

DE 145126267

TI Inhibition of hepatitis C replicon RNA synthesis by  $\beta$ -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication

AD Sluyver, Steven J.; McBrayer, Tamara P.; Tharish, Phillip M.; Clark, Jeremy; Holleker, Laurent; Lostia, Stefania; Nachman, Tommy; Grier, Jason; Bennett, Matthew A.; Xie, Meng-Yu; Schinazi, Raymond P.; Morrey, John D.; Julander, Justin L.; Furman, Phillip A.; Otto, Michael J.

CS Pharmasset Inc, Princeton, NJ, USA

SO Antiviral Chemistry & Chemotherapy (2006), 17(2), 79-87

COGEM: ACCHEM; ISBN: 0956-3202

PE International Medical Press, Ltd.

PT Journal

LA English

AB  $\beta$ -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine (F81-6130) is a cytidine analog with potent and selective anti-hepatitis C virus (HCV) activity in the subgenomic HCV replicon assay, 50% effective concentration (EC50) ~ 4.6  $\pm$  2.0  $\mu$ M. The spectrum of activity and cytotoxicity profile of F81-6130 was evaluated against a diverse panel of viruses and cell types, and against two addl. HCV-1b replicons. The S282T mutation, which confers resistance to 2'-C-Me adenosine and other 2'-methylated nucleosides, showed only a 6.9-fold increase in EC50. When assayed for activity against bovine diarrhoea virus (BVDV), which is typically used as a surrogate assay to identify compds. active against HCV, F81-6130 showed no anti-BVDV activity. Weak antiviral activity was noted against other flaviviruses, including West Nile virus, Dengue type 2, and yellow fever virus. These results indicate that F81-6130 is a specific inhibitor of HCV. F81-6130 showed little or no cytotoxicity against various cell types, including human peripheral blood mononuclear and human bone marrow progenitor cells. No mitochondrial toxicity was observed with F81-6130. The reduced activity against the RdRp S282T mutant suggests that F81-6130 is an inhibitor of replicon RNA synthesis. Finally, the no-effect dose for mice treated i.p. with F81-6130 for six consecutive days was  $\geq$ 100 mg/kg per day.

IT 517204-33-4, F81 6130


PL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOG (Biological study); USES (Uses)

(F81-6130 inhibition of hepatitis C replicon RNA synthesis)

RM 517204-33-4 CAPLUS

CB Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'P)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE/CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 AUGUST 7 OF 10 CAPLUS COPYRIGHT 2007 ACS OR STM

AN 20061269477 CAPLUS

DN 144:312289

TI Preparation of silyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs via condensation of the lactone to nucleosides as potential antiviral agents

IN Chun, Byoung-Kwon; Wang, Peiyuan

PA Pharmasset, Inc., USA

SO PCT Int. Appl., 74 pp.

COGEM: PEXD2

PT Patent

LA English

FAU.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	NO 2006031725	A2	20060323	NO 2005-052406	20050913
	*i: AE, AG, AL, AM, AT, AU, AZ, BA, BE, BG, BR, BW, BY, BZ, CB, CH,				

CG, CH, CI, CJ, CK, CL, CM, CN, CO, CP, CQ, CR, CS, CT, CU, CV, CW, CX, CY, CZ, DA, DB, DC, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT, DU, DV, DW, DX, DY, DZ, EA, EB, EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL, EM, EN, EO, EP, EQ, ER, ES, ET, EU, EV, EW, EX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GF, GH, GI, GJ, GK, GL, GM, GN, GO, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LL, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MM, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NN, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TT, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UU, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ.

PA: AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AM, AN, AO, AP, AQ, AR, AS, AT, AU, AV, AW, AX, AY, AZ, BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BK, BL, BM, BN, BO, BP, BQ, BR, BS, BT, BU, BV, BW, BX, BY, BZ, CA, CB, CC, CD, CE, CF, CG, CH, CI, CJ, CK, CL, CM, CN, CO, CP, CQ, CR, CS, CT, CU, CV, CW, CX, CY, CZ, DA, DB, DC, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT, DU, DV, DW, DX, DY, DZ, EA, EB, EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL, EM, EN, EO, EP, EQ, ER, ES, ET, EU, EV, EW, EX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GF, GH, GI, GJ, GK, GL, GM, GN, GO, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LL, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MM, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NN, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TT, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UU, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ.

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -- AVAILABLE VIA OFFLINE PRINT \*

AB A process for preparing of 2-deoxy-2-fluoro-2-methyl-D-ribofuranosyl, I, wherein R1 and R2 can independently be H, CH3, acetyl, benzoyl, pivaloyl, 4-nitrobenzoyl, 3-nitrobenzoyl, 2-nitrobenzoyl, 4-chlorobenzoyl, 3-chlorobenzoyl, 2-chlorobenzoyl, 4-methylbenzoyl, 3-methylbenzoyl, 1-methylbenzoyl, 4-phenylbenzoyl, benzyl, 4-methoxybenzyl, trityl, trialkylsilyl, t-butyl-dialkylsilyl, t-butyl-diphenylsilyl, TIPDS, THP, MOM, or SEM are prepared and used in the condensation to 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs. Thus, 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs II and III, wherein X is a halogen; Y is N or CH; Z is a halogen, hydroxyl, ether, thiol, thioether, (un)substituted amine or alkyl; R1' is alkyl, vinyl, ethynyl; R2' and R3' can be same or different H, alkyl, arylalkyl, acyl, cyclic acetal such as 2',3'-O-isopropylidene or 2',3'-O-benzylidene, or 2',3'-cyclic carbonate; R4, R5, and R6 are independently H, halogen, hydroxyl, ether, thiol, thioether, N3, (un)substituted amine, (un)substituted amide, alkyl, halogenated alkyl, alkenyl, halogenated alkenyl, alkynyl, halogenated alkynyl, hydroxy alkyl, alkoxy are prepared and are potential anti-HCV agents. Specifically, IV was prepared in 88 % yield via condensation, alkylation and stereoselective fluorination reactions and can exhibit potential use as an anti-HCV agent.

IT 878581-07-20  
RI: (MF) (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation);

(preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs via condensation of the lactone to nucleosides)

AN 872551-07-2 CAPIAS

ON Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-bis(2,2-dimethylpropanoate), (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



hydroxyl, ether, thiol, thioether, (un)substituted amine or alkyl; X1' is alkyl, vinyl, ethynyl; X2' and X3' can be same or different H, alkyl, arylalkyl, acyl, cyclic acetal such as 2',3'-O-isopropylidene or 2',3'-O-benzylidene, or 2',3'-cyclic carbonate; R4, X5, and X6 are independently H, halogen, hydroxyl, ether, thiol, thioether, N1, (un)substituted amine, (un)substituted amide, alkyl, halogenated alkyl, alkenyl, halogenated alkenyl, alkynyl, halogenated alkynyl, hydroxy alkyl, alkoxy are prepared and are potential anti-HCV agents. Specifically, IV was prepared (no yield, claimed) via condensation, alkylation and stereoselective fluorination reactions and can exhibit potential use as an anti-HCV agent.

IT 817204-32-3F 817204-33-4F 874638-82-1F

874638-84-9D 874638-98-3F


RL: TMP (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs via condensation of the lactone to nucleosides)

HN 817204-32-1 CAPLUS

CH Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoyl-, (2'H)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



FN 817204-33-4 CAPLUS

CH Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'H)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



HN 874638-82-1 CAPLUS

CR Benzamide, N-[1-[(2R)-5-O-benzoyl-2-deoxy-2-fluoro-2-methyl-3-O-(methylsulfonyl)-β-D-erythro-pentofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




101828-253

XN 874638-94-5 C39L03

CN Benzazwido, 9-[1-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-methyl- $\alpha$ -D-  
 erythro-pentofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9Cl) (C8 INDEX  
 NAME)


### Absolute stereochemistry



NO 874638-98-3 CAPLUS

CA Cytidine, 3-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, (2'E)- (9CI) (CA INDEX  
BASE)

Absolute stereochemistry.



14 ABSTRACT 9 OF 10 CAPLOS COPYRIGHT 2007 ACS on STP

AN 2009:040160 CASALIS

[illegible]

73 Design, Synthesis, and Antiviral Activity of 2'-deoxy-2'-fluoro-2'-C-methyl-cytidine, a Potent Inhibitor of Hepatitis C Virus Replication

Clark, Jeremy D.; Hollecker, Laurent; Meson, J. Christian; Stuyver, Kieven  
J.; Tharnish, Phillip M.; Lontia, Stefania; McBrayer, Tamara K.; Schineai,  
Paymond E.; Watanabe, Kyoichi A.; Otco, Michael J.; Porman, Phillip A.;  
Steer, Wojciech J.; Patterson, Steven E.; Hankiewicz, Krzysztof W.

C3 Pharmasset, Inc., Princeton, NJ, 08540, USA

50 *Journal of Medicinal Chemistry* (2005), 48(17), 5504-5508

OSBEN; JONAS; 1838; 0022-2623

FD American Chemical Society

Dr. Joanna

CS. English

09 CREDIT 143:248807

AB The pyrimidine nucleoside-  $\beta$ -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine (1) was designed as a hepatitis C virus RNA-dependent RNA polymerase (NS5B RdRp) inhibitor. The title compound was obtained by a S&T fluorination of 84-benzoyl-1-(2-methyl-3,5-di-O-benzoyl- $\beta$ -D-arabinofuranosyl)cytosine to provide 84-benzoyl-1-(2-fluoro-2-methyl-3,5-di-O-benzoyl- $\beta$ -D-ribofuranosyl)cytosine. The protected 2'-C-methylcytidine was obtained as a byproduct from the S&T fluorination and allowed for the preparation of two high active compounds from a common precursor. Compound 1 and 2'-C-methylcytidine were assayed in a sub-genomic HCV replicon assay system and found to be potent and selective inhibitors of HCV replication. Compound 1 shows increased inhibitory activity in the HCV replicon assay compared to 2'-C-methylcytidine and low cellular toxicity.

19 817204-13-88

AL: PAC (Pharmacological activity); PCT (Reactant); SPN (Synthetic preparation); EIGL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(design, synthesis via fluorination, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl-cytidine, a potent inhibitor of Hepatitis C virus replication)


No later than

16/828,753

BN 817204-33-4 CAPLUS

CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 863329-66-2P


PL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(design, synthesis via fluorination, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl-cytidine, a potent inhibitor of Hepatitis C virus replication)

BN 863329-66-2 CAPLUS

CN Uridine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 817204-32-3P 863329-65-1P


PL: PCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PACT (Reactant or reagent)

(design, synthesis via fluorination, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl-cytidine, a potent inhibitor of Hepatitis C virus replication)

BN 817204-32-3 CAPLUS

CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




BN 863329-65-1 CAPLUS

CN Uridine, 2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

10/878,753




17 817204-38-9P

EL: GPM (Synthetic preparation); PREP (Preparation)  
(design, synthesis via fluorination, and antiviral activity of  
2'-deoxy-2'-fluoro-2'-C-methyl-cytidine, a potent inhibitor of  
Hepatitis C Virus replication)

BN 817204-38-9 CAPLUS

CG Cytidines, 2'-deoxy-2'-fluoro-2'-methyl-, monohydrochloride, (2'R)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● 801

PE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LA ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005134765 CAPLUS

BN 142194074

TX Preparation of modified fluorinated (2'E)-2'-deoxy-2'-fluoro-2'-C-methyl  
nucleoside analogs as antiviral agents

ID Clark, Jeremy

PA Pharmasset, Ltd., Barbados

SO PCR Int. Appl., 228 pp.

COBES: PIXXD2

UT Patent


LA English

PAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005003147	A2	20050113	WO 2004-0812472	20040421
WO 2005003147	A3	20050303		
W:	AE, AG, AL, AM, AT, AD, AZ, BA, BB, BG, BR, BW, BY, BE, CA, CB, CN, CO, CR, CU, CZ, DE, DM, DK, EC, EE, EG, ES, FI, GB, GD, GP, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MF, MN, MW, MX, MY, NZ, OA, OI, NO, OG, OM, OS, PA, PE, PL, PT, PG, PH, SC, SD, SE, SG, SI, SJ, SK, SM, SN, TH, TR, TT, TZ, UA, UG, US, VJ, VN, YU, ZA, ZM, ZW			
RW:	BK, CH, CM, CY, CS, DE, DK, EE, EG, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, RU, SE, SF, TH, TR, UA, UG, US, VJ, VN, YU, ZA, ZM, ZW			
AD 2005253860	A2	20050113	AD 2004-253860	20040421
BV 2004253860	A1	20050113		
CA 2527657	A1	20050113	CA 2004-2527657	20040421
US 2005009737	A1	20050113	US 2004-828753	20040421
EP 1633766	A2	20050315	EP 2004-775900	20040421
R:	AT, BE, CH, DE, DK, EE, FR, GB, GR, IT, LI, LU, NL, SE, NO, PT, SK, SI, SM, SN, TH, TR, UA, UG, US, VJ, VN, YU, ZA, ZM, ZW			

Mc16085






● KCI


IT 817204-44-7  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); RXOL  
 (Biological study); USES (Uses)  
 (preparation of modified fluorinated (2'R)-2'-deoxy-2'-fluoro-2'-C-Me  
 nucleoside analogs as antiviral agents)  
 RN 817204-44-7 CASPLUS  
 CN Cytidine 5'-((tetrahydrogen triphosphate), 2'-deoxy-2'-fluoro-2'-methyl-,  
 (2'R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 817204-32-3P 817204-37-8P  
 RL: KCT (Reactant); SPB (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of modified fluorinated (2'R)-2'-deoxy-2'-fluoro-2'-C-Me  
 nucleoside analogs as antiviral agents)  
 RN 817204-32-3 CASPLUS  
 CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoyl-,  
 (2'R)- (BCI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 817204-37-8 CASPLUS  
 CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-  
 bis(trifluoroacetate), (2'R)- (BCI) (CA INDEX NAME)

Absolute stereochemistry.

10/828,753



→ d Als

(FILE 'HOUSE' ENTERED AT 15:01:03 ON 27 DEC 2007)

FILE 'REGISTRY' ENTERED AT 15:01:44 ON 27 DEC 2007

L1 STRUCTURE UPLOADED

L2 0 5 L1 BSB BAM

L3 19 6 L1 FULL

FILE 'CAPLUS' ENTERED AT 15:02:41 ON 27 DEC 2007

L4 10 8 L3